Main Article Content
Immunocompromised cancer patients are at significant risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A method to identify those patients at highest risk is needed so that prophylactic measures may be employed. Serum antibodies to SARS-CoV-2 spike protein are important markers of protection against COVID-19 disease. We evaluated total and neutralizing antibody levels pre and post third booster vaccine and compared responses among different cancer-bearing and healthy veterans. This as a prospective, single site, comparative cohort observational trial. The setting was the West Palm Beach VA Medical Center cancer center. All veterans received a third SARS-CoV-2 mRNA booster. The main outcomes were anti-SARS-CoV-2 spike IgG and neutralizing antibodies to wild-type, and B.1.617, BA1, BA2, and BA4/5 variants were measured. Disease type and therapy, COVID-19 infection, and anti-CD20 antibody treatments were documented. The third mRNA vaccine booster increased the mean blood anti-spike IgG five-fold. The second anti-spike level was equal or greater than the first in 129/140 veterans. All the groups except the myeloma group, had post-booster antibody levels significantly higher than pre-booster with 4-fold, 12-fold, 4-fold, 6-fold and 3.5-fold increases for the control, solid tumor, CLL, B cell lymphoma and all B cell malignancy cohorts. The myeloma set showed only a non-significant 1.7-fold increase. Recently anti-CD20 antibody-treated patients were shown to have approximately 200-fold less anti-S IgG production after vaccine booster than other patients. There was a 2.5-fold enhancement of wild-type virus mean neutralizing antibodies after a third mRNA booster and mean neutralization of Delta and Omicron variants increased 2.2, 6.5, 7.7, and 6.2-fold versus pre-boost levels. B cell malignancies failed to show increased post-booster neutralization. The third SARS CoV-2 booster increased total anti-spike IgG and neutralizing antibodies for most subjects. Veterans with B cell malignancies particularly myeloma and those receiving anti-CD20 monoclonal antibodies had the weakest humoral responses. Neutralizing antibody responses to Omicron variants were less than for wild-type virus. A subset of patients without humoral immunity post-booster should be considered for prophylactic antibody or close monitoring.
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
2. Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. Seroconversion rate following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021; 39(8): 1081-1090.
3. Addeo A, Shah PK, Bordry N et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021; 39(8): 1091-1098.
4. Fendler A, Shepherd STC, Au L, et al. Omicron neutralizing antibodies after third COVID-19 vaccine dose in patients with cancer. Lancet 2022; 399(10328): 905-907.
5. Zeng C, Evans JP, Chakravarthy K, et al. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. Cancer Cell. 2022; 40: 117-119.
6. Bellusci L, Grubbs G, Srivastava P, et al. Neutralization of SARS-CoV-2 omicron after vaccination of patients with myelodysplastic syndromes or acute myeloid leukemia. Blood. 2022; 139(18): 2842-2846.
7. Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021; 184: 476-488.
8. Harvey RA, Rassen JA, Kabelac CA, et al. Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med. 2022; 181(5): 672-679.
9. Lumley SF, O’Donnell D, Stoesser NE, et al. Antibody status and incidence of SARS-CoV-2 infection on health care workers. New Engl J Med. 2021. 384(6): 533-540.
10. Cromer D, Steain M, Reynaldi A, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2022; 3: e52-e61.
11. Bayram A, Demirbakan H, Guenl Karadeniz P, et al. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol. 2021; 93(9): 5560-5567.
12. Huang D, Tran JT, Pang L, et al. A rapid assay for SARS-CoV-2 neutralizing antibody that is insensitive to antiretroviral drugs. J Immunol. 2021; 207(1): 344-351.
13. Rottenberg Y, Grinshpun A, Ben-Dov IZ, et al. Assessment of response to a third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment. JAMA Oncol. 2022; 8(2): 300-301.
14. Shapiro LC, Thakkar A, Campbell ST, et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2022; 40:3-5.
15. Debie Y, Vandamme T, Goossens ME, et al. Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer. Eur J Cancer. 2022; 163: 177-179.
16. Mair MJ, Berger JM, Mitterer M, et al. Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events—a retrospective cohort study. Eur J Cancer. 2022; 165: 184-194.
17. Feng Sh, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Med. 2021; 27: 2032-2040.
18. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022; 375: 43-50.
19. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27:1205-1211.
20. Lumley SF, O’Donnell, Stoesser NE, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. New Engl J Med. 2021; 384(6): 533-540.
21. Case JB, Mackin S, Errico J, et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. bioRxiv, 2022; 03.17.484787.
22. Soni A, Herbert C, Filippaios A, et al. Comparison of rapid antigen tests’ performance between Delta (B1.61.7;AY.X) and Omicron (B.1.1.529;BA1) variants of SARS-CoV-2: secondry analysis from a serial home self-testing study. medRxiv. 2022; 02.27.22271090.
23. Greasley SE, Noell S, Plotnikova O, et al. Structural basis for nirmatrelvir in vitro efficacy against the SARS-CoV-2 variants. J Biol Chem. 2022; Epub, April 19.
24. Rowe M, Bondzie EA, Powers O, et al. Neutralization escape by SARS-CoV-2 virus subvariant BA2.12.1, BA.4 and BA.5. New Engl J Med. 2022; Epub, June 22.